{"prompt": "['69', 'MC1488 WEE1', 'MCCC', 'Active-Monitoring Phase', '(Compliance with Test Schedule Section 4.0)', 'CRF', 'At each evaluation during', 'At end of treatment', 'treatment', 'Patient Questionnaire Booklet Compliance', 'X2', 'X', 'Research Blood Submission', 'X (see Section 14.0)', 'X', 'Research Bone Marrow Aspirate Submission', 'X (see Section 14.0)', 'PK Specimen Submission (Cycle 1)', 'X (see Section 14.0) (Cycle 1', 'only)', 'PK Specimen Submission (Cycle 2+)', 'X', 'X (see Section 14.0) (Cycle', '2+)', 'End of Active Treatment/Cancel Notification', 'X', 'Notification- Grade 4 or 5 Non-AER', 'At each occurrence', 'Reportable Events/Hospitalization', '(see Section 10.0)', 'ADR/AER', 'At each occurrence', '(see Section 10.0)', '1. Patient questionnaire booklet must be used; copies are not acceptable for this submission. To be', 'completed prior to treatment every cycle.', '2. This form must be completed only if the patient questionnaire booklet contains absolutely NO patient', 'provided assessment information.', '3. Submit copy of documentation of response (CR, CRi, PR, CI, MLFS, Marrow CR) or', 'PD/Relapse/Fail/Failure, Attention', 'Follow-up Material(s)', 'Event Monitoring Phase\u00b9', 'After', 'CRF', 'q.', '3', 'PD q.', 'months', '6', 'until PD\u00b2', 'At PD\u00b2', 'mos.', 'Death', 'New Primary', 'Event Monitoring', 'X', 'X', 'X', 'X', 'At each occurrence', '1. If a patient is still alive 2 year after registration, no further follow-up is required.', '2. Submit copy of documentation of response or progression to the MCCC Operations Office, Attention:', '19.0', 'Budget Considerations', '19.1', 'Costs charged to patient: all standard of care tests and procedures such as physical exams,', 'blood CBC and chemistries, bone marrow biopsies, AraC drug and administration costs,', 'etc', '19.2', 'Tests to be research funded: research blood and bone marrow collection and processing, AZD1775', 'drug dispensing']['70', 'MC1488 WEE1', 'MCCC', '19.3 Other budget concerns: Drug and PK analysis will be supported by AstraZeneca.', '20.0', 'References', 'Abe Y. et al, Hedgehog signaling overrides p53-mediated tumor suppression by activating', 'Mdm2. Proc Natl Acad Sci US A. 2008 Mar 25;105(12):4838-43.', 'Aaronson NK, Ahmedzai S, Bergman B, et al. (1993) The European Organization for Research and', 'Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials', 'in oncology. Journal of the National Cancer Institute; 85: 365-76.', 'Ahnert JR, Baselga J, Tawbi A et al (2010) A phase I dose-escalation study of LDE225, a smoothened', '(Smo) antagonist, in patients with advanced solid tumors. J Clinical Oncol 28:15s (Supple; abstr', '2500)', 'Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced', 'myelodysplastic syndromes. Cancer. 1989 Nov 166(9):1812-8.', 'Bai, L. Y. et al. Differential expression of Sonic hedgehog and Glil in hematological malignancies.', 'Leukemia 22, 226-228, (2008).', 'Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. (199) Quality of life in head and neck cancer patients:', 'validation of the European Organization for Research and Treatment of Cancer Quality of Life', 'Questionnaire-H&N35. Journal of Clinical Oncology; 17: 1008-19.', 'Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 424 Phase 1 Dose-Escalation Study of PF-', '04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies', 'Bolwell BJ, Cassileth PA, Gale RP. Low dose cytosine arabinoside in myelodysplasia and acute', 'myelogenous leukemia: a review. Leukemia. 1987 Aug;1(8):575-9.', 'Burnett, A.K., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans', 'retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not', 'considered fit for intensive treatment. Cancer 109, 1114-1124 (2007).', 'Cavelier C, Didier C, Prade N, Mansat-De Mas V, Manenti S, Recher C, Demur C, Ducommun B.', 'Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with', 'complex karyotype: potential importance for checkpoint targeting therapy. Cancer Res. 2009 Nov', '15;69(22):8652-61.', 'Catriona Jamieson\u00b9 Jorge E. Cortes\u00b2, Vivian Oehler, MD\u00b3, Michele Baccarani, MD4 Hagop M.', 'Kantarjian5, Cristina Papayannidis Kristen N. Rice, MD7, Xiaoxi Zhang Naveed Shaik*9', 'Rachel Courtney, PhD* 10 , Wendy J. Levin, MD, MS*,1 and Giovanni Martinelli, MD11', 'Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside', 'in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol.', '1986 Dec;4(12):1857-64.', 'Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, Schiffer CA, Doehner H,', 'Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA,', 'L\u00f6wenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for']\n\n###\n\n", "completion": "END"}